BioSpace News Archive

Merck has announced its vaxneuvance for pneumococcal disease in infants and has met key safety, tolerability, and immunogenicity endpoints in the first 30 days.

BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that it has launched a new, fully automated high-throughput diagnostic system using robotics and sample management software algorithms to set a new standard in automation for infectious disease molecular testing in core laboratories and other centralized laboratories in the United States.

Silence Therapeutics to Participate in September Investor Conferences 25 August 2021

Merck today announced topline results from the pivotal PNEU-PED (V114-029) study evaluating the immunogenicity, safety and tolerability of VAXNEUVANCE™

Global Cord Blood Corporation today announced that it plans to release financial results for the first quarter fiscal 2022 on Monday, August 30, 2021, after the market close.

Design Controls brings product development and quality management together in one simplified and traceable cloud-based quality management system

NeoImmuneTech, Inc. today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).

Visus Therapeutics Appoints Industry Leaders Tracy Valorie and Dwight Moxie to Board of Directors

Frontiers in Digital Health recently published a longitudinal study designed to evaluate digital musculoskeletal (MSK) program usage and outcomes by generation.

Kintor Pharmaceutical Limited today announced that it has entered into a licensing agreement with PT Etana Biotechnologies Indonesia, on the commercialization of proxalutamide